Sodium tungstate

Drug Profile

Sodium tungstate

Alternative Names: Wolframio

Latest Information Update: 02 May 2007

Price : $50

At a glance

  • Originator University of Barcelona
  • Developer Bayer; University of Barcelona
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 14 May 2003 No development reported - Preclinical for Diabetes mellitus in Spain (unspecified route)
  • 31 Jan 2002 A study has been added to the pharmacokinetics section
  • 03 Dec 2001 Bayer has acquired the patent rights for sodium tungstate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top